What is Your Risk of Contracting Alzheimer’s Disease? A Telematics Tool Helps you to Predict it

  • Rodrigo Méndez-Sanz
  • Isabel de la Torre-Díez
  • Miguel López-Coronado
Patient Facing Systems
Part of the following topical collections:
  1. Patient Facing Systems


Alzheimer’s disease (AD) is the most common dementia in developed countries. Between the identified risk factors, one of the most important is the age. Its prevalence reaches 24 % in men and 33 % in women over 85 years. Increase in life expectancy, making it a serious public health problem. Prevention of Alzheimer’s disease represents a major challenge to health. Given that Alzheimer’s disease is largely dependent on the genetics of each person and uninterrupted progress of the age, which is try to make people aware that there are other factors that can alter your chance of developing the Alzheimer disease and although currently not reduce, help is not increased in the near or distant future.

The aim of this paper is to develop and evaluate a Web-Mobile application (Alzhe Alert) used to calculate the risk of Alzheimer’s from a short questionnaire using a computer or mobile device, so that any user, without requiring computer skills, can access the website to estimate their risk of developing the disease in the coming years depending on their habits and daily basis activities. The users who have realized the questionnaire can to observe in a graph the result, and they will know which is at risk for Alzheimer’s at present and over the next 50 years if they continue with the same habits and lifestyle. The objective is that the users can be aware of the risk they have different habits of life about their health. Currently, 243 users (84 women and 159 men) of white race have completed the questionnaire. 76 % of the users have got a risk below the average.


Alzheimer e-Health Prevention Risk Web-mobile 



This research has been partially supported by Ministerio de Economía y Competitividad, Spain.

Conflicts of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Thies, W., Alzheimer’s disease neuroimaging initiative: A decade of progress in Alzheimer’s disease. Alzheimers Dement. 11(7):727–729, 2015.PubMedCrossRefGoogle Scholar
  2. 2.
    De Pedro-Cuesta, J., Virués-Ortega, J., Vega, S., et al., Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990–2008. BMC Neurol. 9:55, 2009.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Castellani, R. J., and Perry, G., Pathogenesis and disease-modifying therapy in Alzheimer’s disease: The flat line of progress. Arch. Med. Res. 43(8):694–698, 2012.PubMedCrossRefGoogle Scholar
  4. 4.
    Della Mea, V., What is the e-health (2): The death of telemedicine? J. Med. Internet Res. 3(2):e22, 2001.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    da Silva Lopes, H. F., Abe, J. M., and Anghinah, R., Application of paraconsistent artificial neural networks as a method of aid in the diagnosis of Alzheimer disease. J. Med. Syst. 34(6):1073–1081, 2010.PubMedCrossRefGoogle Scholar
  6. 6.
    Daliri, M. R., Automated diagnosis of Alzheimer disease using the scale-invariant feature transforms in magnetic resonance images. J. Med. Syst. 36(2):995–1000, 2012.PubMedCrossRefGoogle Scholar
  7. 7.
    Ferri, C. P., Prince, M., Brayne, C., et al., Global prevalence of dementia: A Delphi consensus study. Lancet 366(9503):2112–2117, 2005.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    World Health Organization (2015) Neurological Disorders: Public Health Challenges. Accessed 2 October 2015
  9. 9.
    O’Brien J., Ames D., Burns A., Dementia Second Edition: London, 2000.Google Scholar
  10. 10.
    Bu, G., Apolipoprotein E and its receptors in Alzheimer’s disease: Pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10(5):333–344, 2009.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Selkoe, D. J., Alzheimer’s disease: Genes, proteins, and threrapy. Physiol. Rev. 81:741–766, 2001.PubMedGoogle Scholar
  12. 12.
    Levy-Lahad, E., and Dird, T. D., Genetic factors in Alzheimer’s disease: A review of recent advances. Ann. Neurol. 40(6):829–840, 2004.CrossRefGoogle Scholar
  13. 13.
    Li, Y. J., Scott, W. K., Hedges, D. J., Zhang, F., Gaskell, P. C., et al., Age at onset in two common degenerative diseases is genetically controlled. Am. J. Hum. Genet. 70(4):985–993, 2002.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Viña, J., and Lloret, A., Why women have more Alzheimer’s disease than men: Gender and mitochondrial toxicity of amyloid-beta peptide. J. Alzheimers Dis. 20(Suppl 2):S527–533, 2010.PubMedGoogle Scholar
  15. 15.
  16. 16.
    Bortolon, C., Louche, A., Gély-Nargeot, M. C., and Raffard, S., Do patients suffering from Alzheimer’s disease present an own-age bias in face recognition? Exp. Gerontol. 70:46–53, 2015.PubMedCrossRefGoogle Scholar
  17. 17.
    Raggi, A., Tasca, D., Panerai, S., Neri, W., and Ferri, R., The burden of distress and related coping processes in family caregivers of patients with Alzheimer’s disease living in the community. J. Neurol. Sci. 2015. doi: 10.1016/j.jns.2015.08.024.Google Scholar
  18. 18.
    Newell, K. L., Silver, M. H., Perls, T. T. and Hedley-Whyte, E. T., What centenarians teach us about neuropathology. In: JM Martinez Lage and V Hachinski (Eds.), Envejecimiento cerebral y enfermedad. Editorial Triacastela: 31–46. Madrid, Spain, 2001.Google Scholar
  19. 19.
    Launer, L., and Hofman, A., Frequency and impact of neurologic diseases in the elderly of Europe: A collaborative study of population-based cohorts. Neurology 54(11 Suppl 5):S1–8, 2000.PubMedGoogle Scholar
  20. 20.
    Whalley, L. J., Starr, J. M., Athawes, R., Hunter, D., Pattle, A., and Deary, I. J., Childhood mental ability and dementia. Neurology 55(10):1455–1459, 2000.PubMedCrossRefGoogle Scholar
  21. 21.
    Larson, E. B., Dementia in the elderly: The “silent epidemic” no more. Trans. Am. Clin. Climatol. Assoc. 112:136–148, 2001.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Durazzo, T. C., et al., Smoking and increased Alzheimer’s disease risk: A review of potential mechanisms. Alzheimers Dement. 10(3):S122–S145, 2014.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Chen, R., Association of environmental tobacco smoke with dementia and Alzheimer’s disease among never smokers. Alzheimers Dement. 8(6):590–595, 2012.PubMedCrossRefGoogle Scholar
  24. 24.
    Brust, J. C., Ethanol and cognition: Indirect effects, neurotoxicity and neuroprotection: A review. Int. J. Environ. Res. Public Health 7(4):1540–1557, 2010.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Del-Aguila, J. L., Koboldt, D. C., Black, K., Chasse, R., Norton, J., Wilson, R. K., and Cruchaga, C., Alzheimer’s disease: Rare variants with large effect sizes. Curr. Opin. Genet. Dev. 2015. doi: 10.1016/j.gde.2015.07.008.PubMedGoogle Scholar
  26. 26.
    Xu, W., Tan, L., Wang, H. F., Jiang, T., Tan, M. S., Tan, L., Zhao, Q. F., Li, J. Q., Wang, J., and Yu, J. T., Meta-analysis of modifiable risk factors for Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 2015. doi: 10.1136/jnnp-2015-310548.Google Scholar
  27. 27.
    Lu, F. P., Lin, K. P., and Kuo, H. K., Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. PLoS One 4(1):e4144, 2009.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Rönnemaa, E., Zethelius, B., et al., Glucose metabolism and the risk of Alzheimer’s disease and dementia: A population-based 12 year follow-up study in 71-year-old men. Diabetologia 52(8):1504–1510, 2009.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Rodrigo Méndez-Sanz
    • 1
  • Isabel de la Torre-Díez
    • 1
  • Miguel López-Coronado
    • 1
  1. 1.Department of Signal Theory and Communications, and Telematics EngineeringUniversity of ValladolidValladolidSpain

Personalised recommendations